Polymyxin antibiotics for gram-negative infections

American Journal of Health-System Pharmacy

Volumn 64, Issue 8, 2007, Pages 819-826

  Arnold, Tamra M ^a   Forrest, Graeme N ^b,c   Messmer, Karen J ^a  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Antibiotics; Drug use; Gram negative bacterial infections; Hospitals; Polymyxin; Rational therapy; Resistance; Toxicity

Indexed keywords

CEFTAZIDIME; COLISTIMETHATE; COTRIMOXAZOLE; POLYMYXIN; POLYMYXIN B; RIFAMPICIN;

ACUTE KIDNEY TUBULE NECROSIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UREMIA;

EID: 34247250198     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060473     Document Type: Review

References (62)

1. Eggimann P, Pittet D. Infection control in the ICU. Chest. 2001; 120:2059-93.
2. Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest. 1999; 115(suppl 3):34S-41S.
3. Lim SM, Webb SA. Nosocomial bacterial infections in intensive care units. I: organisms and mechanisms of antibiotic resistance. Anaesthesia. 2005; 60:887-902.
4. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003; 36:592-8.
5. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003; 36:1433-7.
6. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings: why a campaign? www.cdc.gov/drugresistance/healthcare/problem.htm (accessed 2006 Jul 9).
7. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003; 17:545-62.
8. Wilkinson S. Identity of colistin and polymyxin B. Lancet. 1963; 1:922-3.
9. Hoeprich PD. The polymyxins. Med Clin North Am. 1970; 54:1257-65.
10. Polymyxin B for injection prescribing information. Bedford, OH: Bedford Laboratories; 2004.
11. Feeley TW, du Moulin GC, Hedley J et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975; 293:471-5.
12. Goodwin NJ. Colistin and sodium colistimethate. Med Clin North Am. 1970; 54:1267-76.
13. Coly-Mycin M Parenteral (Colistimethate for Injection, USP) prescribing information. Bristol, TN: Monarch Pharmaceuticals, Inc.; 2002.
14. Littlewood JM, Miller MG, Ghoneim AT et al. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis. Lancet. 1985; 1:865. Letter.
15. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa infection by early treatment. Lancet. 1991; 338:725-6.
16. Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am. 1982; 66:135-42.
17. Lorian V. The mode of action of antibiotics on gram-negative bacilli. Arch Intern Med. 1971; 128:623-32.
18. Catchpole CR, Andrews JM, Brenwald N et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother. 1997; 39:255-60.
19. McGowan JE, Garner C, Wilcox C et al. Antibiotic susceptibility of gram-negative bacilli isolated from blood cultures. Am J Med. 1974; 57:225-38.
20. Li J, Turnidge J, Milne R et al. In-vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001; 45:781-5.
21. Eickhoff TC, Finland M. Polymyxin B and colistin: in-vitro activity against Pseudomonas aeruginosa. Am J Med Sci. 1965; 249:172-4.
22. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999; 43:1317-23.
23. Trotman RL, Williamson JC, Shoemaker DM et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005; 41:1159-66.
24. Curtis JR, Eastwood JB. Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis. Br Med J. 1968; 1:484-5.
25. Greenberg PA, Sanford JP. Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate. Ann Intern Med. 1967; 66:465-70.
26. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2005; 49:4814-5.
27. Sarria JC, Angulo-Pernett F, Kimbrough RC et al. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis. 2004; 23:340-1.
28. Ryan KJ, Schainuck LI, Hickman RO et al. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA. 1969; 207:2099-101.
29. Koch-Weser J, Sidel VW, Federman EB et al. Adverse effects of sodium colestimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 72:857-68.
30. Goury-Laffont M. [Colimycin in nephritis.] Chemotherapia. 1962; 5:136-43. In French.
31. Taylor G, Allison H. Colymycin - laboratory and clinical investigations. Br Med J. 1962; 2:161-3.
32. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med. 1964; 270:1030-5.
33. Price DJ, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J. 1970; 4:525-7.
34. Randall RE, Bridi GS, Setter JG et al. Recovery from colistimethate nephrotoxicity. Ann Intern Med. 1970; 73:491-2.
35. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother. 1964; 23:552-74.
36. Kurihara T, Takeda H, Ito H et al. [Studies on the compounds related to colistin. IX. On the chemical deacylation of colistin and colistin derivatives.] Yakugaku Zasshi. 1974; 94:1491-4. In Japanese.
37. Danner RL, Joiner KA, Rubin M et al. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother. 1989; 33:1428-34.
38. Falagas ME, Kasiakou SK. Toxicity of the polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006; 10:R27-40.
39. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 1998; 41:494-5.
40. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2001; 40:117-20.
41. Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother. 2004; 16:282-7.
42. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 2002; 44:259-63.
43. Gunderson BW, Ibrahim KH, Horde LB et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in-vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003; 47:905-9.
44. Timurkaynak F, Can F, Azap O et al. In-vitro activities of non-traditional antimicrobials alone or in combination against multi-drug resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents. 2004; 27:224-8.
45. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob. 2006; 5:10.
46. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984; 26:539-45.
47. Denton M, Kerr K, Mooney L et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol. 2002; 34:257-61.
48. Ciofu O, Giwercman B, Pedersen SS et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF center. APMIS. 1994; 102:674-80.
49. Landman D, Bratu S, Alam M et al. City-wide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother. 2005; 55:954-7.
50. Performance standards for antimicrobic disc susceptibility tests. Approved standard M2-A2 S2. Wayne, PA: National Committee for Clinical Laboratory Standards; 1981.
51. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41.
52. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001; 39:183-90.
53. Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005; 43:903-5.
54. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999; 33:960-7.
55. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999; 28:1008-11.
56. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002; 21:212-4.
57. Segal-Maurer S, Mariano N, Qavi A et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and renew. Clin Infect Dis. 1999; 28:1134-8.
58. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis. 2002; 35:901-2. Letter.
59. Ouderkirk JP, Nord JA, Turett GS et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003; 47:2659-62.
60. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care. 2003; 7:R78-83.
61. Berlana J, Llop JM, Fort E et al. Use of colistin in the treatment of multiple-drug resistant gram-negative infections. Am J Health-Syst Pharm. 2005; 62:39-47.
62. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez J et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003; 36:1111-8.